Cetuximab-dependent ADCC in cancer: dream or reality?
Ottaiano
Alessandro
A
Scala
Stefania
S
Iaffaioli
Vincenzo Rosario
VR
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000920:Antibody-Dependent Cell Cytotoxicity; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068818:Cetuximab; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068818:Cetuximab